BIOA (BioAge Labs, Inc.) PDUFA Date | FDA Catalyst & Approval Status

Jul 14, 2026

BioAge Labs administra la primera dosis a un participante en el ensayo de fase 2 de BGE-102

BioAge Labs has administered the first dose to a participant in the Phase 2 trial of BGE-102, an oral NLRP3 inhibitor aimed at reducing cardiovascular risk. The trial, QUELL-CV, is designed to evaluate the drug's efficacy and determine the optimal dose for future phases. Preliminary data is expected in the second half of 2026.

Jul 14, 2026

BioAge Labs, Partner von HitGen, verabreicht erste Dosis an Teilnehmer der Phase-2-Studie zu BGE-102, einem neuartigen oralen NLRP3-Inhibitor zur Senkung des kardiovaskulären Risikos

BioAge Labs has administered the first dose of BGE-102 in a Phase 2 study aimed at reducing cardiovascular risk. This novel oral NLRP3 inhibitor, developed in partnership with HitGen, shows promise based on Phase 1 results. The study will help determine the optimal dosage for future Phase 3 trials, with topline data expected in late 2026.

Jul 14, 2026

HitGen Partner BioAge Labs Doses First Participant in Phase 2 Trial of BGE-102, a Novel Oral NLRP3 Inhibitor for Cardiovascular Risk Reduction

BioAge Labs has initiated dosing in the Phase 2 QUELL-CV trial for BGE-102, an oral NLRP3 inhibitor aimed at reducing cardiovascular risk. This follows promising Phase 1 results that indicated significant reductions in hsCRP levels. The trial is designed to optimize dosing for future Phase 3 studies, with results expected later in 2026.

Jun 16, 2026

BioAge Labs Announces First Participant Dosed in QUELL-CV, a Phase 2 Proof-of-Concept Trial of BGE-102, a Novel Oral NLRP3 Inhibitor, in Patients at Elevated Cardiovascular Risk

BioAge Labs has initiated the QUELL-CV trial, dosing its first participant with BGE-102, a novel oral NLRP3 inhibitor aimed at reducing cardiovascular risk. This Phase 2 proof-of-concept trial will evaluate the drug's efficacy in participants with elevated systemic inflammation. Topline data is expected in the second half of 2026, building on promising Phase 1 results.

May 22, 2026

BioAge Labs to Present at Upcoming Investor Conferences

BioAge Labs, Inc. (NASDAQ: BIOA) has announced its participation in upcoming investor conferences, including the Jefferies Global Healthcare Conference and the Goldman Sachs Global Healthcare Conference. Key executives will engage in discussions and one-on-one meetings, showcasing the company's focus on developing therapies for metabolic diseases through the biology of aging. The company anticipates releasing Phase 2 cardiovascular risk data by late 2026 and additional proof-of-concept data for diabetic macular edema by mid-2027. This highlights BioAge's commitment to innovative approaches in biopharmaceutical development.

May 8, 2026

BioAge Labs Reports First Quarter 2026 Financial Results and Provides Business Updates

BioAge Labs reported positive Phase 1 data for its NLRP3 inhibitor BGE-102, showing significant reductions in cardiovascular risk biomarkers. The company plans to initiate two proof-of-concept trials in mid-2026. Additionally, BioAge completed a successful public offering, raising $132.3 million to support its development programs. However, the company also reported a net loss of $22.3 million for the first quarter of 2026.

May 4, 2026

BioAge to Host R&D Day Focused on NLRP3 Inhibition on May 8, 2026

BioAge Labs, Inc. announced it will host an R&D Day webcast on May 8, 2026, to present Phase 1 clinical data for BGE-102, a novel NLRP3 inflammasome inhibitor. The event will include insights from leading experts on its therapeutic implications for atherosclerotic cardiovascular disease (ASCVD) and retinal disease. Following the presentations, there will be a live Q&A session, aimed at engaging with attendees and discussing the latest developments in NLRP3 biology. The webcast will be accessible via their investor relations website and is positioned to enhance understanding of BGE-102’s potential in clinical settings.

Apr 21, 2026

BioAge Reports Positive Phase 1 Data for BGE-102, a Novel Oral NLRP3 Inhibitor, Demonstrating Potential Best-in-Class Reductions in hsCRP

BioAge Labs reported promising Phase 1 clinical trial results for its novel oral NLRP3 inhibitor, BGE-102, which achieved significant reductions in high-sensitivity C-reactive protein (hsCRP) among participants with obesity and inflammation. The study demonstrated a well-tolerated profile, with both 60 mg and 120 mg doses achieving impressive biomarker reductions. Looking ahead, BioAge plans to initiate Phase 2 trials focused on cardiovascular risk and diabetic macular edema by mid-2026 and mid-2027, respectively, aiming to leverage BGE-102's potential across various indications.

Apr 14, 2026

BioAge Labs to Present at 25th Annual Needham Virtual Healthcare Conference

BioAge Labs, Inc. will present at the 25th Annual Needham Virtual Healthcare Conference from April 13-16, 2026. CEO Kristen Fortney will lead a fireside chat on April 16, while other executives will engage in one-on-one meetings. The company focuses on developing therapies for metabolic diseases linked to human aging.

BioAge Labs Reports Full Year 2025 Financial Results and Provides Business Updates from the Fourth Quarter of 2025 Positive interim Phase 1 data for BGE-102, a potent, structurally novel, orally available, brain-penetran

BioAge Labs reported positive interim Phase 1 data for BGE-102, a new NLRP3 inhibitor, highlighting its potential for cardiovascular risk reduction. The company plans to initiate a Phase 2a trial in 2026 and has expanded BGE-102's indication to ophthalmology, targeting diabetic macular edema. Additionally, BioAge completed a $132.3 million follow-on public offering, strengthening its financial position despite a reported net loss of $80.6 million for 2025. The results and upcoming trials suggest a robust pipeline and ongoing clinical development.

Mar 23, 2026

New data on long-term, real-world treatment with lecanemab presented at the 2026 AD/PD™ congress

At the 2026 AD/PD congress, BioArctic and Eisai presented new data on lecanemab, highlighting a significant 78.4% treatment persistence rate at 18 months among early Alzheimer's patients. The findings align with previous Phase 3 study outcomes, suggesting that long-term treatment can lead to better clinical results. Additionally, BioArctic showcased an innovative screening strategy for their exidavnemab trial.

Feb 19, 2026

BioAge Labs to Present at Oppenheimer 36th Annual Healthcare Life Sciences Conference

BioAge Labs, a clinical-stage biotechnology company, announced its participation in the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 25-26, 2026. CEO Kristen Fortney will take part in a fireside chat on February 26, alongside CFO Dov Goldstein who will meet with investors. The company is focused on developing therapeutic candidates targeting metabolic diseases, with its lead product, BGE-102, currently in Phase 1 clinical trials.

BioAge Announces Indication Expansion for Oral NLRP3 Inhibitor BGE-102, with Plans to Initiate Phase 1b/2a Proof-of-Concept Clinical Trial in Patients with Diabetic Macular Edema in Mid-2026

BioAge Labs announced the expansion of its BGE-102 program into ophthalmology, targeting diabetic macular edema (DME) with a planned Phase 1b/2a proof-of-concept trial set to begin in mid-2026. BGE-102 is an orally administered NLRP3 inhibitor that has shown promising results in reducing inflammatory biomarkers. The trial aims to demonstrate ocular target engagement, with results expected by mid-2027.

BioAge Announces Proposed Public Offering

BioAge Labs, Inc. has announced a proposed public offering to raise up to $75 million in common stock, with an additional option for underwriters to purchase $11.25 million more. The funds will support research and development of its product candidates, including BGE-102. The offering is subject to market conditions and regulatory approvals.

Jan 21, 2026

▼ -5.6%on this newsshared move

BioAge Announces Pricing of Upsized $115.0 Million Public Offering

BioAge Labs, Inc. has announced the pricing of an upsized public offering, raising approximately $115 million through the sale of nearly 5.9 million shares at $19.50 per share. The offering is scheduled to close on January 23, 2026. Funds raised will support research, clinical development, and manufacturing of their product candidates, particularly BGE-102. BioAge's efforts focus on addressing metabolic diseases linked to human aging through innovative therapies.

Jan 13, 2026

▲ +15.9%on this news· ran to +28% by day 1

BioAge Announces Additional Positive Interim Phase 1 Data for BGE-102, a Novel Brain-Penetrant NLRP3 Inhibitor, Demonstrating Potential for Best-in-Class hsCRP Reduction in Participants with Elevated Cardiovascular Risk

BioAge Labs announced positive interim results from its Phase 1 trial of BGE-102, a novel NLRP3 inhibitor. The trial showed an 86% reduction in hsCRP levels among obese participants with elevated cardiovascular risk. Additionally, BGE-102 demonstrated significant reductions in IL-6 and fibrinogen, with a favorable safety profile. The company plans to advance BGE-102 into a Phase 2a study in the first half of 2026.

Dec 4, 2025

▲ +13.9%on this news· ran to +31% by day 3

BioAge Announces Positive Interim Phase 1 Data for BGE-102, a Novel Brain-Penetrant NLRP3 Inhibitor

BioAge Labs announced positive interim results from its Phase 1 trial of BGE-102, a novel NLRP3 inhibitor. The drug showed strong target engagement with significant suppression of IL-1β and high brain penetration. The trial is being expanded to include multiple ascending dose cohorts in obese participants, with further data expected in 2026.

Nov 25, 2025

BioAge Labs to Present at Piper Sandler 37th Annual Healthcare Conference

BioAge Labs, Inc. will present at the Piper Sandler 37th Annual Healthcare Conference in New York from December 2-4, 2025. CEO Kristen Fortney and CFO Dov Goldstein will engage in a fireside chat and one-on-one meetings. The company is focused on developing therapies for metabolic diseases, with its lead candidate BGE-102 currently in a Phase 1 trial.

Nov 7, 2025

BioAge Labs to Present at Jefferies Global Healthcare Conference in London

BioAge Labs, Inc. will present at the Jefferies Global Healthcare Conference in London from November 17-20, 2025. CEO Kristen Fortney and CFO Dov Goldstein will engage in a fireside chat and hold one-on-one meetings. The company is focused on developing therapies for metabolic diseases, including its lead candidate BGE-102.

Nov 6, 2025

BioAge Labs Reports Third Quarter 2025 Financial Results and Provides Business Updates First participant dosed in Phase 1 trial of BGE-102, oral CNS-penetrant NLRP3 inhibitor, with initial SAD data expected by year-end C

BioAge Labs provided its third quarter 2025 financial results, highlighting the dosing of the first participant in the Phase 1 trial for BGE-102, an NLRP3 inhibitor. Initial single ascending dose data is expected by year-end 2025. Alongside this, the company is advancing its APJ agonist programs with plans for 2026 IND submissions. Financial results indicate a reduced net loss compared to the previous year, while collaboration revenue increased due to a partnership with Novartis. BioAge's current cash position is projected to suffice until 2029.

Oct 2, 2025

BIOAGE INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. Continues Investigation into BioAge Labs, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C. is investigating BioAge Labs, Inc. for potential fiduciary breaches following a class action complaint related to the company's IPO. This investigation comes after BioAge announced the discontinuation of its STRIDES Phase 2 trial for azelaprag, its lead candidate, due to safety concerns. The announcement led to a significant decline in the company's stock price, highlighting the impact of the trial's discontinuation on investor confidence.

Aug 15, 2025

BioAge Labs Announces First Participant Dosed in Phase 1 Clinical Trial of BGE-102, a Novel Brain-Penetrant NLRP3 Inhibitor

BioAge Labs has initiated a Phase 1 clinical trial for BGE-102, a novel NLRP3 inhibitor aimed at treating obesity. The trial will assess the drug's safety, tolerability, and pharmacokinetics in healthy participants. Preclinical studies have shown promising weight loss results, with initial data expected by the end of 2025.

Aug 6, 2025

BioAge Labs Reports Second Quarter 2025 Financial Results and Provides Business Updates Oral NLRP3 inhibitor BGE-102 on track for Phase 1 initiation in 2H 2025 with initial data by year-end Expanded APJ agonist pipeline

BioAge Labs reported its financial results for Q2 2025 and outlined significant business progress. The company is preparing to initiate Phase 1 clinical trials for its oral NLRP3 inhibitor BGE-102, which has displayed promising weight loss results in preclinical studies. Additionally, BioAge expanded its APJ agonist pipeline through a partnership with JiKang Therapeutics and announced the profiling of over 17,000 samples from the HUNT Biobank. While R&D expenses increased significantly, the company continues to innovate and enhance its therapeutic offerings in metabolic diseases.

Jul 3, 2025

BIOAGE ALERT: Bragar Eagel & Squire, P.C. is Investigating BioAge Labs, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C. is investigating potential claims against BioAge Labs, Inc. following a class action complaint filed in January 2024. The investigation focuses on possible breaches of fiduciary duties by the company's board, particularly after BioAge announced the discontinuation of the STRIDES Phase 2 trial for its lead product candidate, azelaprag, due to safety issues. This announcement resulted in a dramatic decline in BioAge's stock price.

Jun 21, 2025

BioAge Labs to Present Preclinical Data on APJ Agonism for Diabetic Obesity and Heart Failure at the American Diabetes Association (ADA) 85th Scientific Sessions

BioAge Labs announced preclinical data on apelin receptor agonism for diabetic obesity and heart failure, to be presented at the ADA's 85th Scientific Sessions. The data indicates that APJ activation enhances glycemic control and offers cardioprotective benefits, particularly in combination with incretin therapies. BioAge is developing next-generation APJ agonists with an IND filing planned for 2026.

Jun 17, 2025

BioAge Labs Expands Drug Discovery Platform with Data from Leading European Biobank

BioAge Labs has announced a new initiative to analyze over 17,000 samples from the HUNT Biobank in Norway. This collaboration aims to deepen insights into the biology of aging and resilience, potentially leading to novel therapeutic targets for aging-related diseases. The data will enhance BioAge's existing drug discovery platform, which utilizes extensive human aging data.

Jun 3, 2025

BioAge Expands APJ Agonist Pipeline with Oral Small-Molecule and Long-Acting Biologic Candidates

BioAge Labs has entered an option agreement with JiKang Therapeutics to in-license a novel APJ agonist nanobody, indicating a strategic expansion of its pipeline aimed at addressing metabolic diseases linked to obesity. The company has also filed a provisional patent for new small molecule APJ agonists designed for oral administration, showcasing its commitment to innovation in this therapeutic area. With preclinical data suggesting enhanced weight loss outcomes, BioAge aims to submit an Investigational New Drug application by 2026. The collaboration with JiKang signals a strong move towards clinical applications for these candidates.

May 29, 2025

BioAge Labs completes IND-enabling studies for BGE-102, a potent, orally available, brain-penetrant NLRP3 inhibitor, and advances candidate toward the clinic

BioAge Labs, Inc. has completed IND-enabling studies for its compound BGE-102, a small-molecule NLRP3 inhibitor aimed at treating obesity. The company plans to submit an Investigational New Drug application in mid-2025, with initial Phase 1 data expected by the end of the same year. Preclinical results indicate that BGE-102 can induce significant weight loss, both on its own and in combination with GLP-1 receptor agonists, showing potential as a novel treatment option for metabolic diseases related to aging and inflammation.

May 6, 2025

BioAge Labs Reports First Quarter 2025 Financial Results and Provides Business Updates ● Advancement of lead candidate BGE-102, an oral, brain-penetrant NLRP3 inhibitor for obesity, with initial clinical data expe

BioAge Labs reported its first quarter 2025 financial results, marking strategic advancement in its pipeline, notably with lead candidate BGE-102, an innovative NLRP3 inhibitor for obesity. The company emphasized strong collaborations, including a new partnership with Lilly ExploR&D aimed at developing novel therapeutic antibodies. While financial results indicated a net loss, BioAge's substantial cash reserves suggest that it can sustain its operations through 2029. The company provided updates on various development programs, including promising progress in research activities.

Mar 20, 2025

BioAge Labs Reports Full Year 2024 Financial Results and Provides Business Updates from the Fourth Quarter of 2024 Advancement of oral, brain-penetrant NLRP3 inhibitor BGE-102, with initial clinical data expected 2H25 Pr

BioAge Labs announced its financial results for the full year 2024 and highlighted advancements in its pipeline, including the oral NLRP3 inhibitor BGE-102, with initial clinical data expected by the second half of 2025. The company discontinued its development of the APJ agonist azelaprag due to observed liver transaminitis in clinical trials but is advancing distinct next-generation APJ agonists. BioAge established strategic partnerships with Novartis and Lilly to develop novel therapies targeting metabolic diseases driven by aging. Despite a significant net loss for the year, the company maintains a strong cash position, anticipating sufficient funds through 2029.

Mar 7, 2025

BioAge Labs (BIOA) Abandons Obesity Drug Amid Shareholder Lawsuit – Hagens Berman

BioAge Labs (BIOA) has decided to abandon its lead obesity drug candidate, azelaprag, following the termination of its Phase 2 trial due to safety concerns. This decision coincides with a class action lawsuit that claims the company misled investors in its September 2024 IPO, which raised $227.7 million. Shareholders allege that BioAge's disclosures failed to address potential risks associated with the drug. The company's stock price has plummeted more than 76% since the announcement of the trial's cessation.

Mar 5, 2025

BioAge Labs, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses. March 10, 2025 Deadline to file Lead Plaintiff Motion

BioAge Labs, Inc. is facing a class action lawsuit following the discontinuation of its Phase 2 trial for azelaprag due to safety concerns raised over liver transaminase levels. Investors who acquired BioAge securities during the initial public offering in September 2024 have until March 10, 2025, to file a lead plaintiff motion. The discontinuation announcement was unexpected and triggered a drastic decline in the company's stock price. The Portnoy Law Firm is advising affected investors on their legal rights and options for recovering losses.

Mar 4, 2025

BioAge Labs, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before March 10, 2025 to Discuss Your Rights – BIOA

Levi & Korsinsky, LLP has initiated a class action lawsuit against BioAge Labs, Inc. regarding alleged securities fraud affecting investors of the company. The lawsuit pertains to shareholders who purchased stock related to BioAge's IPO on September 26, 2024. Negative news about the discontinuation of the STRIDES Phase 2 trial for azelaprag due to safety concerns resulted in a steep decline in the company's stock price from $20.09 to $4.65 within a day. Investors affected by this are encouraged to contact the firm before the March 10, 2025 deadline to discuss recovery options.

Mar 3, 2025

▼ -6.7%on this newsshared move

BioAge Labs (BIOA) Shares Plummet After Discontinuing Trial Just 2 Months After IPO– Hagens Berman

BioAge Labs, Inc. has decided to discontinue its lead obesity candidate, azelaprag, just months after its IPO. This follows the termination of a Phase 2 trial due to safety issues, specifically elevated liver enzymes in some trial participants. The company is facing a class action lawsuit from investors who claim misleading statements were made during the IPO process. With shares plummeting over 76%, BioAge is refocusing its efforts on a preclinical neuroinflammation program but must navigate the legal challenges ahead.

Mar 3, 2025

▼ -6.7%on this newsshared move

BIOAGE LABS, INC. (NASDAQ: BIOA) DEADLINE ALERT: Bernstein Liebhard LLP Reminds BioAge Labs, Inc. Investors of Upcoming Deadline

BioAge Labs, Inc. is under scrutiny due to a securities fraud class action lawsuit related to its IPO on September 26, 2024. Bernstein Liebhard LLP is reminding investors of the upcoming deadline to join the lawsuit, which claims misrepresentations regarding BioAge's STRIDES Phase 2 clinical trial of its lead product candidate, azelaprag. Investors who acquired shares are encouraged to discuss their legal rights as the lawsuit progresses.

Feb 26, 2025

BioAge Labs, Inc. Class Action: The Gross Law Firm Reminds BioAge Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 10, 2025 – BIOA

The Gross Law Firm has announced a pending class action lawsuit on behalf of shareholders of BioAge Labs, Inc. (BIOA). This follows BioAge's discontinuation of its STRIDES Phase 2 trial for azelaprag due to safety concerns that emerged shortly after the company went public. The stock saw a significant decline in value as a result of the announcement, falling from $20.09 to $4.65. The law firm encourages shareholders to register for potential participation in the lawsuit, with a lead plaintiff deadline set for March 10, 2025.

Feb 21, 2025

BioAge Labs, Inc. Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky Before March 10, 2025 to Discuss Your Rights – BIOA

BioAge Labs, Inc. is facing a class action securities lawsuit due to alleged fraud affecting investors. The lawsuit concerns shareholders who purchased stock around the time of BioAge's IPO in September 2024. A significant decline in the company's stock price occurred after the discontinuation of the Phase 2 trial for its lead product azelaprag, attributed to safety concerns regarding liver transaminase levels. Investors have until March 10, 2025, to request to be appointed lead plaintiff in the case.

Feb 20, 2025

BioAge Labs to Participate in TD Cowen's 45th Annual Health Care Conference

BioAge Labs (Nasdaq: BIOA) has announced its participation in TD Cowen's 45th Annual Health Care Conference, scheduled for March 3–5, 2025, in Boston, MA. The event will feature various presentations and discussions about the health care industry. BioAge Labs is known for developing therapeutic products aimed at metabolic diseases through the biology of human aging, which includes a pipeline of innovative drug candidates.

Feb 14, 2025

▲ +6%on this newsshared move

BioAge Labs (BIOA) Faces Securities Class Action On Behalf Of IPO Investors After Discontinuing Weight-Loss Drug Trial – Hagens Berman

BioAge Labs (BIOA) is the subject of a class-action lawsuit following the cessation of its STRIDES Phase 2 clinical trial for azelaprag due to safety concerns. Investors allege that the company misled them regarding the drug's safety and potential for success in earlier IPO communications. Following the announcement of trial discontinuation, BioAge's stock price saw a significant decline of more than 76%. The lawsuit, filed in California, points to possible violations of securities laws due to these claims.

Feb 12, 2025

BioAge Labs (BIOA) Faces Securities Class Action On Behalf Of IPO Investors After Discontinuing Weight-Loss Drug Trial– Hagens Berman

BioAge Labs (BIOA) is being sued in a class-action lawsuit for allegedly misleading investors about the safety of its drug candidate before its IPO. The lawsuit claims that the company provided false information regarding the STRIDES Phase 2 trial for azelaprag, leading to a 76% drop in stock value after the trial was halted due to safety concerns. The lead plaintiff deadline for the lawsuit is March 10, 2025, prompting calls for investors to submit their losses.

Jan 29, 2025

▼ -6.4%on this newsshared move

BioAge Labs, Inc. Securities Fraud Class Action Lawsuit Pending: Contact The Gross Law Firm Before March 10, 2025 to Discuss Your Rights – BIOA

BioAge Labs, Inc. is currently facing a securities fraud class action lawsuit related to its lead product candidate, azelaprag. The lawsuit follows the company's announcement on December 6, 2024, that it would discontinue the STRIDES Phase 2 trial due to safety concerns that surprised investors, resulting in a significant stock price drop. Shareholders who purchased shares during the class period are encouraged to register for participation in the lawsuit before the March 10, 2025 deadline.

Jan 28, 2025

BioAge Labs Announces Company Updates on APJ, NLRP3, and Platform Programs

BioAge Labs has announced several updates regarding their development programs, including the discontinuation of the APJ agonist azelaprag due to safety concerns. The company has nominated its NLRP3 inhibitor BGE-102 as a new development candidate, with initial clinical data expected by the end of 2025. Furthermore, BioAge is expanding its collaborations with Novartis and Lilly to enhance its research efforts targeting metabolic diseases connected to human aging. The company's financial position remains robust with significant cash reserves ensuring operational stability beyond 2029.

Jan 26, 2025

BioAge Labs, Inc. (BIOA) Investors: March 10, 2025 Filing Deadline in Securities Class Action - Contact Kessler Topaz Meltzer & Check, LLP

BioAge Labs, Inc. is embroiled in a securities class action lawsuit filed in the U.S. District Court for the Northern District of California. The lawsuit alleges the company made false or misleading statements regarding its STRIDES Phase 2 trial for azelaprag, specifically concerning safety data and expected trial outcomes. Investors who purchased shares during the IPO period are urged to respond before the March 10, 2025, deadline for lead plaintiff applications. The law firm Kessler Topaz Meltzer & Check, LLP is handling the case.

Jan 23, 2025

BioAge Labs, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses. March 10, 2025 Deadline to file Lead Plaintiff Motion.

BioAge Labs, Inc. is facing a class action lawsuit due to the abrupt discontinuation of its STRIDES Phase 2 trial for azelaprag, which was announced on December 6, 2024. This decision was attributed to safety concerns regarding elevated liver transaminase levels in participants. Investors are encouraged to contact the Portnoy Law Firm to consider their legal rights, with a deadline set for filing a lead plaintiff motion by March 10, 2025. The company's stock experienced a drastic decline from $20.09 per share to $4.65 shortly after the announcement.

Jan 21, 2025

BioAge Labs, Inc. Sued for Securities Law Violations - Contact The Gross Law Firm Before March 10, 2025 to Discuss Your Rights – BIOA

BioAge Labs, Inc. is facing a lawsuit over alleged securities law violations following the discontinuation of its STRIDES Phase 2 trial for azelaprag. The trial was halted due to safety concerns involving elevated liver transaminase levels in participants. This announcement caused a significant drop in the company's stock price, falling sharply from $20.09 to $4.65. Shareholders impacted during the IPO class period are encouraged to register for potential lead plaintiff status by March 10, 2025.

Jan 17, 2025

BioAge Labs, Inc. Class Action Notice: Robbins LLP Reminds Stockholders of the Lead Plaintiff Deadline in the BIOA Class Action

Robbins LLP has filed a class action on behalf of shareholders of BioAge Labs, Inc. (BIOA) regarding claims that the company misled investors about its lead drug candidate, azelaprag, during its initial public offering. Allegations include the failure to disclose potential safety concerns related to liver damage observed in trials, which resulted in a substantial decline in the company’s stock price. A lead plaintiff must be appointed by March 10, 2025, for the class action case.

Jan 8, 2025

▼ -5%on this newsshared move

BIOAGE ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against BioAge Labs, Inc. and Encourages Investors to Contact the Firm

A class action lawsuit has been filed against BioAge Labs, Inc. following the company's decision to discontinue the STRIDES Phase 2 trial for its lead product candidate, azelaprag, due to safety concerns. This announcement, made on December 6, 2024, resulted in a significant decline in BioAge's stock price from $20.09 to $4.65. Investors are encouraged to contact the law firm Bragar Eagel & Squire for more information regarding their participation in the lawsuit, which affects those who purchased shares during the company's recent IPO.

Jan 8, 2025

▼ -5%on this newsshared move

BIOAGE LABS, INC. (NASDAQ: BIOA) INVESTOR ALERT: Investors With Large Losses in BioAge Labs, Inc. Should Contact Bernstein Liebhard LLP To Discuss Their Rights

Bernstein Liebhard LLP has initiated a class action lawsuit on behalf of investors in BioAge Labs, Inc. (NASDAQ: BIOA), alleging misrepresentations related to its STRIDES Phase 2 clinical trial of azelaprag. The lawsuit claims the company did not adequately disclose relevant information regarding the trial's outcomes. Investors who purchased BioAge shares during the company's IPO are encouraged to discuss their rights and may seek to serve as lead plaintiffs. The deadline for filing papers is March 10, 2025.

Jan 3, 2025

BioAge Labs Investigation: Investors are Alerted the Company is Being Investigated after Phase 2 Trial Results – Contact BFA Law if You Lost Money (NASDAQ:BIOA)

BioAge Labs, Inc. is currently under investigation for potential violations of federal securities laws following the discontinuation of its STRIDES Phase 2 trial for azelaprag. The trial was halted due to safety concerns, specifically the emergence of liver transaminitis in participants. Following this announcement, BioAge's stock experienced a dramatic decline of over 76%. Investors are encouraged to seek legal advice regarding potential losses.

BioAge Labs (BIOA) Azelaprag Trial Halt Raises Questions About Pre-IPO Disclosures – Hagens Berman

BioAge Labs, Inc. (BIOA) has halted its Phase 2 clinical trial for azelaprag, a treatment for obesity, just months after its IPO. This decision has sparked an investigation by Hagens Berman regarding the company's disclosures about the drug's safety prior to the announcement. Following this news, BioAge's stock price fell nearly 80%, prompting concerns from investors and regulatory scrutiny of the company's transparency. The investigation aims to determine whether investors were adequately informed about the safety profile of azelaprag during its earlier trials.

Dec 24, 2024

BIOAGE ALERT: Bragar Eagel & Squire, P.C. is Investigating BioAge Labs, Inc. on Behalf of BioAge Stockholders and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C. is investigating BioAge Labs, Inc. on behalf of its stockholders regarding potential violations of federal securities laws. The investigation comes after BioAge discontinued its STRIDES Phase 2 trial for azelaprag, citing safety concerns related to elevated liver transaminase levels in participants. Following the news, BioAge's shares dramatically dropped by more than 76.8%. Investors are encouraged to reach out to the law firm for more information on the situation.

Dec 23, 2024

BioAge Labs Investors Who Have Lost Money Should Contact Block & Leviton to Find Out How They Might Recover Money Through The Firm’s Investigation

Block & Leviton is probing BioAge Labs, Inc. for possible securities law violations after the company's shares plummeted by 73%. The drop was triggered by the cessation of its STRIDES Phase 2 trial for azelaprag, due to safety issues related to elevated liver transaminase levels in participants. The news comes shortly after BioAge's IPO, during which it promoted azelaprag's potential benefits in obesity therapy. Investors who have incurred losses are encouraged to contact Block & Leviton for potential recovery options.

Dec 18, 2024

BioAge Labs Announces Multi-Year Collaboration with Novartis to Discover Novel Targets for Therapies that Address Age-Related Diseases and Conditions

BioAge Labs has entered a multi-year collaboration with Novartis to discover novel therapeutic targets for age-related diseases. The partnership will utilize BioAge's human longevity data alongside Novartis' expertise in exercise biology. The agreement includes up to $20 million in upfront payments and up to $530 million in potential future milestones. This collaboration aims to enhance the understanding of aging biology and develop treatment options for age-related conditions.

Dec 10, 2024

BioAge Labs, Inc. ALERT: Securities Fraud Investigation by Block & Leviton Could Allow Investors to Recover Losses

Block & Leviton is currently investigating BioAge Labs, Inc. for potential securities law violations after the company discontinued its azelaprag Phase 2 trial due to safety concerns. This decision led to a dramatic 73% drop in the company's stock price on December 9, shocking investors who were initially optimistic about the drug's potential following its recent IPO. Investors who incurred losses are encouraged to contact the firm to explore options for recovery. The situation represents a significant risk for shareholders amid ongoing legal scrutiny.

Dec 6, 2024

▲ +9.4%on this news· ran to -75% by day 1shared move

BioAge Labs Announces Discontinuation of STRIDES Phase 2 Clinical Trial Evaluating Azelaprag in Combination with Tirzepatide for the Treatment of Obesity

BioAge Labs has announced the discontinuation of its STRIDES Phase 2 clinical trial for azelaprag, following safety observations of liver transaminitis in some subjects. While no clinically significant symptoms were noted, the decision underscores the importance of patient safety. The company plans to analyze the data from current trial participants and will communicate updated plans regarding azelaprag in the first quarter of 2025. Despite this setback, BioAge intends to advance its NLRP3 inhibitor program along with other therapeutic initiatives targeting metabolic diseases.

Dec 5, 2024

BioAge Labs to Present at Goldman Sachs “Year-Ahead” Catalyst Clinic

BioAge Labs (Nasdaq: BIOA) will present at Goldman Sachs' Second Annual 'Year-Ahead' Catalyst Clinic on December 19, 2024. The clinical-stage biopharmaceutical company is developing products targeting metabolic diseases linked to aging. Their lead candidate, azelaprag, has shown promise in promoting metabolism and is currently in a Phase 2 trial aimed at treating obesity in older adults. The virtual presentation will be accessible via a live webcast and will be available for replay afterward.

BioAge Labs Reports Third Quarter 2024 Financial Results and Provides Business Updates

BioAge Labs reported its third quarter 2024 financial results and significant business updates, including the initiation of the Phase 2 STRIDES trial for azelaprag in combination with tirzepatide aimed at obesity. The company successfully completed a $238.3 million IPO, providing a strong cash position to fund operations into 2029. Additionally, Jean-Pierre Garnier was appointed as the new Board Chair, signaling a strengthening of its leadership. Despite achieving these milestones, the company recorded a net loss of $23.4 million, highlighting ongoing financial pressures.

BioAge Labs, Inc. Unaudited Condensed Consolidated Balance Sheets (In thousands) September 30

BioAge Labs, Inc. reported its third quarter 2024 financial results and highlighted significant milestones, including the initiation of the Phase 2 STRIDES trial for azelaprag in combination with tirzepatide, targeting obesity management. The company successfully completed an initial public offering, raising $238.3 million, with sufficient cash reserves to fund operations through 2029. However, BioAge reported a net loss of $23.4 million for the quarter, primarily attributed to increased research and development expenditures. They also appointed Jean-Pierre Garnier as the new Board Chair, signaling a strong leadership commitment to their clinical objectives.

Nov 4, 2024

BioAge Labs to Present Preclinical Data for APJ Agonist Azelaprag at ObesityWeek 2024

BioAge Labs announced the presentation of new preclinical data for azelaprag, an oral apelin receptor agonist, at ObesityWeek 2024. The data will demonstrate azelaprag’s potential to enhance weight loss in combination with appetite suppression therapies and to act as an effective monotherapy for obesity-related issues. Key presentations will discuss findings from studies conducted on mice, showing improvements in body composition and metabolic benefits. BioAge is advancing azelaprag through clinical trials aimed at bolstering treatment options for metabolic diseases like obesity.

Oct 24, 2024

BioAge Labs to Present at Jefferies London Healthcare Conference

BioAge Labs, a clinical-stage biopharmaceutical company, has announced that its CEO, Kristen Fortney, will present at the Jefferies London Healthcare Conference from November 19-21, 2024. The presentation will highlight the company's work on therapeutic candidates for metabolic diseases targeting human aging. BioAge’s lead candidate, azelaprag, has demonstrated potential benefits in metabolism and muscle maintenance. An archived replay of the presentation will be made available on the company’s website after the event.

Oct 1, 2024

BioAge Labs Announces Closing of Initial Public Offering, Full Exercise of Underwriters’ Option to Purchase Additional Shares and Closing of the Concurrent Private Placement

BioAge Labs, a clinical-stage biopharmaceutical company, has announced the successful closing of its initial public offering, raising around $238.3 million. This includes the full exercise of the underwriters' option to purchase additional shares. The concurrent private placement further solidified investor interest, involving the sale of 588,888 shares to an existing stockholder. The funds will support BioAge's development of therapies targeting metabolic diseases, especially its lead product candidate, azelaprag, which shows promise for obesity treatment in older adults.

Sep 26, 2024

BioAge Labs Announces Pricing of Upsized Initial Public Offering

BioAge Labs, a clinical-stage biopharmaceutical company, announced the pricing of its upsized initial public offering of 11 million shares at $18.00 each, aiming for gross proceeds of $198 million. The shares will trade on the Nasdaq Global Select Market starting September 26, 2024. BioAge specializes in developing therapies for metabolic diseases, with its notable candidate azelaprag showing positive outcomes in previous trials. The company has also provided underwriters a 30-day option for additional shares.

Dec 3, 2020

BioAge Raises $90M to Treat Aging and Age-related Diseases

Proceeds will support advancement of the company’s pipeline and proprietary platform for identifying and developing therapies to treat diseases of aging Company announces Chief Medical Officer as it prepares to enter clinic in 2021 with lead Phase 2-ready therapeutic compounds

Aug 25, 2020

BioAge Discovers Key Pathway and Identifies Promising Phase 2 Ready Drug to Treat and Reverse Immune Aging, a Root Cause of COVID-19 Morbidity and Mortality in Older Patients

BioAge Plans Phase 2 Clinical trial in Hospitalized COVID-19 Patients Clinical development plan supported by potent inhibition of PGD2 DP1 Receptor by BGE-175, activating immune-modulating mechanisms that result in 100% survival in aged preclinical models of coronavirus BioAge’

Apr 30, 2020